Related Experiment Video
Updated: Aug 16, 2026
09:52
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia
Tatjana Smilevska1, Kostas Stamatopoulos, Maria Samara
1Laboratory of Molecular Genetics and Cytogenetics, University of Thessaly, Larissa, Greece.
Leukemia Research
|August 2, 2005
Summary
Transferrin receptor (TfR) CD71 is highly expressed in most chronic lymphocytic leukemia (CLL) patients, indicating activated neoplastic cells. TfR1 mRNA levels vary, suggesting post-transcriptional regulation in CLL.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Chronic lymphocytic leukemia (CLL) is a mature B-cell malignancy.
- Transferrin receptors (TfRs) play roles in cellular iron uptake and proliferation.
- CD71 is the canonical transferrin receptor 1 (TfR1).
Purpose of the Study:
- To investigate the expression of TfR1 and TfR2 mRNA and CD71 protein in CLL patients.
- To explore the relationship between TfR expression and IGH mutational status in CLL.
- To elucidate the regulation of TfR1 expression in CLL.
Main Methods:
- Analysis of TfR1 and TfR2 mRNA levels using RT-PCR.
- Quantification of CD71 protein expression via flow cytometry.
- Correlation analysis with IGH mutational status.
Main Results:
- High CD71 expression was observed in 95% of analyzed CLL cases.
- All samples expressed TfR1 mRNA.
- TfR2 mRNA variants (alpha/beta) were detected in 52% and 100% of cases, respectively.
- Significant post-transcriptional regulation of TfR1 mRNA was suggested by divergent mRNA levels despite uniform CD71 expression.
- High CD71 expression was prevalent in both IGH-mutated and IGH-unmutated CLL cases.
Conclusions:
- Uniformly high CD71 expression in CLL reflects the activated state of neoplastic cells.
- Post-transcriptional mechanisms likely regulate TfR1 expression in CLL.
- TfR expression patterns may offer insights into CLL cell biology, irrespective of IGH mutational status.
